Ascendis Pharma A/S $ASND is Tri Locum Partners LP’s 4th Largest Position

Tri Locum Partners LP lowered its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 3.7% in the first quarter, Holdings Channel.com reports. The firm owned 255,332 shares of the biotechnology company’s stock after selling 9,683 shares during the period. Ascendis Pharma A/S accounts for 8.2% of Tri Locum Partners LP’s investment portfolio, making the stock its 4th largest holding. Tri Locum Partners LP’s holdings in Ascendis Pharma A/S were worth $58,402,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ASND. Rhumbline Advisers lifted its position in Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after buying an additional 55 shares during the period. Certuity LLC grew its holdings in Ascendis Pharma A/S by 5.7% in the 4th quarter. Certuity LLC now owns 1,170 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 63 shares during the period. Personal CFO Solutions LLC grew its holdings in Ascendis Pharma A/S by 4.4% in the 1st quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 64 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 69 shares during the period. Finally, Farther Finance Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 15.1% during the 4th quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 72 shares during the last quarter.

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime purchased 400 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were purchased at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the acquisition, the director owned 400 shares of the company’s stock, valued at approximately $95,120. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of Ascendis Pharma A/S stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The SEC filing for this sale provides additional information. 40.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Barclays increased their price objective on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Morgan Stanley boosted their target price on shares of Ascendis Pharma A/S from $256.00 to $275.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Wall Street Zen lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Evercore reaffirmed an “outperform” rating and set a $329.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Finally, Weiss Ratings raised shares of Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $296.72.

Ascendis Pharma A/S Price Performance

ASND stock opened at $252.05 on Thursday. The company has a market cap of $15.72 billion, a PE ratio of 29.07 and a beta of 0.37. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. The stock has a 50-day moving average price of $244.94 and a two-hundred day moving average price of $234.50. Ascendis Pharma A/S has a 12-month low of $163.88 and a 12-month high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to analysts’ expectations of $362.47 million. As a group, research analysts predict that Ascendis Pharma A/S will post 4.49 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.